Inmune Bio Inc. (INMB) – Corporate Update
Market Performance
| Metric | Value | Comment |
|---|---|---|
| Closing price (24‑hr period ending 12:47 PM CET, 22 Oct 2026) | USD 1.61 | Up 0.63 % |
| Shares outstanding | 27.8 million | |
| Market capitalisation | USD 44.4 million | |
| Volume (last 24 h) | USD 370.3 k | |
| Year‑to‑date change (last month end) | –25.46 % | |
| 200‑day simple moving average | USD 1.64 | |
| 52‑week high | USD 2.60 (08 Sep 2026) | |
| 52‑week low | USD 1.09 (31 Mar 2026) |
Recent Corporate Actions
Master Services Agreement – On 21 Oct 2026, Inmune Bio entered a master services agreement with Uniphar Durbin Ireland. The agreement establishes a framework for international access, distribution, and potential commercialization of the investigational cell therapy Ebstrocel, intended for recessive dystrophic epidermolysis bullosa.
Regulatory Filings – The company filed a final pre‑marketing authorisation application with the UK Medicines and Healthcare products Regulatory Agency on the same day. The submission supports a potential full marketing authorisation application scheduled for early February 2027, with an anticipated approval decision in mid‑2027, subject to regulatory review.
U.S. Licensing – Parallel preparations are underway for a U.S. biologics licence application, expected in the second quarter of 2027.
Clinical Data – The CORDStrom platform that supports Ebstrocel has shown encouraging safety and symptom‑relief data in early‑stage studies.
These agreements and filings represent the first concrete steps toward advancing Ebstrocel from clinical development to market availability.
Comparison with Peers (Last 24 hrs)
| Symbol | Trade Direction | Current Price | Market Cap (USD mn) |
|---|---|---|---|
| IBIO | +2.44 % | USD 0.84 | 52.8 |
| GANX | 0 % | USD 1.19 | 51.9 |
| TRT | +6.11 % | USD 5.38 | 52.7 |
| AIRG | +1.75 % | USD 4.07 | 52.4 |
| SCOR | –0.87 % | USD 3.41 | 52.2 |
Comscore (SCOR) also reports a price‑earnings ratio of 1.49.
Company Profile
Inmune Bio Inc. is a clinical‑stage biotechnology company headquartered in La Jolla, California. The company focuses on developing cell‑based therapies for cancer and other indications. It is listed on the Nasdaq stock exchange and completed its IPO on 4 Feb 2019. Further information is available on its website, www.inmunebio.com .
